Tech Center 1600 • Art Units: 1616
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18458258 | INHALABLE COMPOSITION OF CLOFAZIMINE AND METHODS OF USE THEREOF | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17772187 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | Non-Final OA | AstraZeneca AB |
| 18539744 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18008837 | Therapeutic Carbon Nanomaterial H2S Oxidants for Biological Polysulfide Synthesis | Final Rejection | The Trustees of Indiana University |
| 18371682 | TRANSPARENT DRESSING WITH HYDROGEL LAYER | Final Rejection | Dukal, LLC |
| 18021374 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE | Non-Final OA | NORTON (WATERFORD) LIMITED |
| 18524116 | Diketopiperazine Salts for Drug Delivery and Related Methods | Non-Final OA | MannKind Corporation |
| 17983915 | DRY POWDER INHALER | Final Rejection | MannKind Corporation |
| 16434938 | COMPOSITION AND METHOD FOR INHALATION | Non-Final OA | MannKind Corporation |
| 18672318 | Inhalable Epinephrine Formulation | Non-Final OA | De Motu Cordis Pty Ltd |
| 17028595 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Non-Final OA | AVALYN PHARMA INC. |
| 17760354 | PRESSURED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Non-Final OA | CHIESI FARMACEUTICI S.P.A |
| 18555813 | LYSINIBACILLUS BACTERIAL STRAIN THAT PROMOTES PLANT GROWTH, AND USE THEREOF | Non-Final OA | Kumiai Chemical Industry Co., Ltd. |
| 18616878 | PHARMACEUTICAL COMPOSITIONS COMPRISING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION | Non-Final OA | VERONA PHARMA PLC |
| 18552838 | MEANS AND METHOD FOR CYTOSOLIC DELIVERY | Non-Final OA | Universiteit Gent |
| 18606272 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | Non-Final OA | KINDEVA DRUG DELIVERY L.P. |
| 17624433 | AEROSOL FORMULATION, CANISTER, AND INHALER CONTAINING THE FORMULATION, AND METHOD OF USE | Final Rejection | KINDEVA DRUG DELIVERY L.P. |
| 18590826 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | Non-Final OA | AstraZeneca Pharmaceuticals LP |
| 18587616 | METHODS FOR THE CONTROL OF POA ANNUA IN WARM SEASON TURFGRASS USING THIENCARBAZONE-METHYL | Non-Final OA | Discovery Purchaser Corporation |
| 18420141 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | Final Rejection | ReCode Therapeutics, Inc. |
| 18282699 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | Final Rejection | ReCode Therapeutics, Inc. |
| 18311274 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | Final Rejection | ReCode Therapeutics, Inc. |
| 18290130 | PLASMA-ACTIVATED MEDIA FOR USE THEREOF IN THE TREATMENT OF RESPIRATORY DISEASES | Non-Final OA | MEDICAL PLASMAS, S.L. |
| 17969250 | PHARMACEUTICAL COMPOSITION | Final Rejection | MEXICHEM FLUOR S.A. DE C.V. |
| 17944666 | PHARMACEUTICAL COMPOSITION | Final Rejection | MEXICHEM FLUOR S.A. DE C.V. |
| 17944637 | PHARMACEUTICAL COMPOSITION | Final Rejection | MEXICHEM FLUOR S.A. DE C.V. |
| 18488375 | PHARMACY COMPOUNDED PRESCRIPTION COMPOSITIONS FOR HAIR GROWTH | Non-Final OA | REMI MEDICAL, LLC |
| 18378743 | CONTROLLED RELEASE OF SUBSTANCES FROM A SOURCE MATERIAL | Final Rejection | Syqe Medical Ltd. |
| 18482309 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | Non-Final OA | RHNanoPharma |
| 18479335 | INTRANASAL DHE FOR THE TREATMENT OF HEADACHE | Final Rejection | Satsuma Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy